Genelux
Develops Olvi-Vec, an oncolytic virus therapy for platinum-resistant ovarian cancer.
Something off on this page? Send us feedback.
Profile
The clinical-stage pipeline centers on Olvi-Vec, a proprietary modified vaccinia-virus candidate designed to kill tumor cells and stimulate immune responses to tumor neoantigens. Its key program is the U.S. OnPrime registrational trial in platinum-resistant or refractory ovarian cancer.
Built from Loma Linda University research, the clinical-stage pipeline of oncolytic viral immunotherapies centers on Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified vaccinia-virus candidate. It is intended to selectively kill tumor cells and stimulate immune responses to each patient's tumor neoantigens.
Olvi-Vec is being evaluated in OnPrime/GOG-3076, a multicenter, randomized, open-label registrational trial for platinum-resistant or refractory ovarian cancer in the United States. The intended product model is an off-the-shelf personalized immunotherapy: one virus product is administered to different patients, with the expected immune response directed to each patient's tumor neoantigens.
Clinical execution of OnPrime is the material operating dependency.
Company facts
Key statistics
Year to date −41.3% · Average volume (30d) 312.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Oct 21, 2025 | Maxim Group | Target | $20 |
| Oct 21, 2025 | Lake Street | Target | $16 |
| Oct 21, 2025 | Loop Capital Markets | Target | $16 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.20 | −$0.21 | −6.8% | — | — | — | +4.18% |
| May 7, 2026Q1 FY26 | −$0.18 | −$0.20 | −11.1% | — | — | — | +9.89% |
| Mar 19, 2026Q4 FY25 | −$0.22 | −$0.24 | −9.1% | $8.0K | $8.0K | 0.0% | −5.51% |
| Nov 5, 2025Q3 FY25 | −$0.23 | −$0.21 | +8.7% | — | — | — | −32.40% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8.0K | $0 | $0 | |
| Gross profit | $0 | −$143.0K | $0 | −$140.0K | −$1.0K | $0 | |
| Operating income | −$7.8M | −$7.8M | −$8.2M | −$9.4M | −$8.4M | −$9.6M | |
| Net income | −$7.5M | −$7.5M | −$8.0M | −$9.2M | −$7.1M | −$9.5M | |
| Diluted EPS | −$0.21 | −$0.20 | −$0.21 | −$0.25 | −$0.22 | −$0.21 | |
| Gross margin | — | — | — | -1,750.0% | — | — | |
| Operating margin | — | — | — | -117,650.0% | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $11.1M · FY23 $170.0K · FY24 $8.0K · FY25 $8.0K
Balance sheet, Jun 30, 2026Cash & short-term investments $18.7M · Total debt $2.4M · Total assets $26.2M · Shareholders' equity $16.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 44.84M · Float 36.13M · 80.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.22M | 9.99% | 13G | Nov 14, 2025 |
| Aladar Szalay | 3.13M | 8.20% | 13G | Feb 17, 2026 |
| Highbridge Capital Management, LLC | 2.50M | 6.80% | 13G | Oct 25, 2024 |
| Woodward Diversified Capital, LLC | 2.12M | 4.72% | 13F | Apr 24, 2026 |
| Vanguard Capital Management LLC | 1.70M | 3.78% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Thomas Zindrick | officer: President and CEO | −3,023 | $2.95 |
| Aug 4, 2026 | Joseph Cappello | officer: Chief Technical Officer | −653 | $2.95 |
| Aug 4, 2026 | Yong Yu | officer: Chief Scientific Officer | −653 | $2.94 |
| Jul 1, 2026 | John W. Smither | director | −12,000 | $2.91 |
| Jun 3, 2026 | Ralph Smalling | officer: Head of Regulatory | −192 | $2.93 |
Peers
- Oncolytics Biotech
Intravenous dsRNA immunotherapy for gastrointestinal tumors
- Replimune Group
HSV-1 oncolytic immunotherapy for solid tumors
- Candel Therapeutics
Adenovirus and HSV immunotherapies for solid tumors
- CG Oncology
Intravesical oncolytic immunotherapy for bladder cancer
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Genelux | $2.66 | −0.31% | $119.3M | — | — | 14,909.4 | −98.2% |
| Oncolytics Biotech | $0.8526 | −0.79% | $86.0M | — | — | — | — |
| Replimune Group | $15.45 | −0.39% | $1.30B | — | — | — | — |
| Candel Therapeutics | $13.07 | +0.08% | $957.6M | — | — | — | — |
| CG Oncology | $73.91 | −0.57% | $6.56B | — | — | 1,052.8 | — |
| Median | — | — | 1,052.8 | — |